BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Sep 23, 2013
Clinical News

Oblean cetilistat regulatory update

Norgine and partner Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA from Takeda for Oblean cetilistat to treat obesity in patients with both Type II diabetes and dyslipidemia. Norgine said...
BC Extra | Sep 21, 2013
Company News

Obesity, pain drugs approved in Japan

Norgine B.V. (Amsterdam, the Netherlands) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Oblean cetilistat to treat obesity in patients with both Type II diabetes and dyslipidemia....
BioCentury | Jul 1, 2013
Finance

3Q Financial Markets Preview: Punctuated equilibrium

Buysiders are viewing 3Q13 as a relatively quiet quarter punctuated by some important clinical and commercial milestones for a few of biotech's bigger names, notably Celgene Corp. and Biogen Idec Inc. The under $200 million...
BC Week In Review | Nov 5, 2012
Clinical News

Cetilistat: Phase III data

The double-blind, Japanese Phase III CCT-002 trial in obese patients with Type II diabetes and dyslipidemia showed that thrice-daily 120 mg cetilistat met the primary endpoint of reducing average body weight from baseline to week...
BC Extra | Oct 31, 2012
Company News

Takeda seeks cetilistat Japanese approval

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for cetilistat to treat obesity in patients with complications of Type II diabetes and dyslipidemia. In the double-blind,...
BioCentury | Feb 7, 2011
Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc. 's Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be...
BC Week In Review | Oct 26, 2009
Company News

Alizyme, Norgine deal

Norgine acquired Alizyme's lead compound cetilistat for £4.6 million ($7.5 million) in cash, plus undisclosed milestones and royalties. The lipase inhibitor has completed Phase II testing for obesity. The deal was brokered by Grant Thornton...
BC Week In Review | Aug 10, 2009
Company News

Alizyme endocrine news

Alizyme entered administration on July 27. The administrators, from Grant Thornton U.K. LLP, said they have been approached by undisclosed parties interested in acquiring lead compound cetilistat . The lipase inhibitor has completed Phase II testing...
BioCentury | Jul 6, 2009
Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 3 mos ended 3/31 4/2/09 Vermillion Inc. (Pink:VRMLQ) Not disclosed $1.9 0.13 9/30/08 $11 (A) Files for Chapter 11 bankruptcy;...
Items per page:
1 - 10 of 62